CAMBRIDGE, Mass., Aug. 26 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today announced the appointment of Kevin Bracken to the position of Vice President of Manufacturing. Bracken will report to Janet Roemer, President and Chief Operating Officer of Verenium's Enzymes Business.
"Kevin brings over 30 years of valuable manufacturing experience from global biotechnology companies," said Roemer. "His extensive background in manufacturing leadership and breadth of expertise in process engineering, facilities and equipment design, project management, contract manufacturing, and commercial scale-up of novel products will greatly benefit Verenium as we work to optimize and expand our manufacturing capabilities."
Prior to joining Verenium, Bracken was Vice President of Manufacturing at Vical Incorporated, a developer of biopharmaceutical products, where he was responsible for all manufacturing activities, served on numerous product development, validation and technical teams for new product candidates, and supervised all scale-up and optimization operations for the company.
Previously, Bracken was Vice President of Process Engineering and Manufacturing at Universal Preservation Technologies, Inc., and was Director of Engineering for Molecular Biosystems. Prior to that, he held positions of increasing responsibility in process engineering with Gilead Sciences and Baxter International. He began his career as an engineer with DuPont.
Bracken received a B.S. in Chemical Engineering from the University of Delaware and a M.S. in Chemical Engineering from the University of Rochester.
About VereniumVerenium Corporation is a pioneer in the development and commercialization of high-performance enzymes for use in industrial processes. &
|SOURCE Verenium Corporation|
Copyright©2010 PR Newswire.
All rights reserved